In short
This article discusses the use of Anti-IL-8 Human Monoclonal Antibody (BMS-986253) in clinical trials for advanced cancers. The drug is being studied in combination with other immunotherapy treatments to evaluate its safety, efficacy, and potential benefits for patients with various types of advanced solid tumors and early-stage colon cancer. These trials aim to determine the optimal dosage, assess treatment responses, and identify potential biomarkers for predicting treatment outcomes.
At a glance
- Drug Name
- Anti-IL-8 Human Monoclonal Antibody (BMS-986253)
- Administration
- Intravenous infusion
- Cancer Types Studied
- Advanced solid tumors, Non-small cell lung carcinoma, Early-stage colon cancer
- Main Objectives
- Safety assessment, Optimal dosage determination, Efficacy evaluation, Biomarker identification
- Combination Therapies
- Nivolumab, Ipilimumab, Relatlimab
- Key Endpoints
- Safety, Feasibility, Pathological response rate, Disease-free survival
- Eligibility Criteria
- Age ≥18, Specific tumor types, Accessible tumor for biopsy, Adequate organ function
What is ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY?
ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY, also known as BMS-986253 or anti-IL8 mAb, is an experimental medication being studied for the treatment of advanced cancers. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-created proteins designed to target specific molecules in the body.
How Does It Work?
This medication works by targeting and blocking interleukin-8 (IL-8), a protein in the body that can promote cancer growth and spread. By inhibiting IL-8, researchers hope to slow down or stop cancer progression. The drug is being studied as part of a new approach called immunotherapy, which aims to boost the body's own immune system to fight cancer.
What Conditions Does It Treat?
ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is currently being investigated for the treatment of: Advanced solid tumors: These are cancers that form solid masses in the body and have spread beyond their original location. Non-small cell lung carcinoma (NSCLC): A type of lung cancer that is being studied in some parts of the clinical trials. Early-stage colon cancer: The drug is being tested as a pre-surgery treatment for patients with colon cancer that has not yet spread to other parts of the body.
Current Clinical Trials
There are currently two main clinical trials studying this medication: A Phase 1/2 study combining ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY with other cancer drugs (nivolumab and ipilimumab) in patients with advanced cancers. This study aims to: Determine the safety and best dose of the medication Evaluate how well the combination treatment works Study how the body processes the drug Measure changes in IL-8 levels in the blood during treatment A Phase 2 study (called the NICHE trial) testing the medication as a pre-surgery treatment for early-stage colon cancer. This study aims to: Assess the safety and feasibility of using immunotherapy before colon cancer surgery Measure how well the treatment shrinks tumors Identify biomarkers that could predict treatment response Study how the treatment affects the immune system in the tumor
How Is It Administered?
ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein. The exact dosing and frequency of administration are still being determined through clinical trials.
Potential Side Effects
As this is an experimental medication, the full range of side effects is not yet known. However, potential side effects may include: Immune-related adverse reactions, as the drug affects the immune system Infusion-related reactions Fatigue Nausea Decreased appetite It's important to note that side effects can vary depending on the individual and the combination of treatments used.
Future Research and Potential
Research on ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY is ongoing, and scientists are exploring its potential in various ways: Combining it with other immunotherapy drugs to enhance effectiveness Using it as a pre-surgery treatment to potentially improve surgical outcomes Identifying biomarkers that could predict which patients are most likely to benefit from the treatment Studying its effects on different types of cancer As research progresses, we may learn more about the drug's effectiveness, optimal dosing, and potential for treating various types of cancer.